Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

COSCIENS Biopharma (CSCI)announced initiation of its Phase 2a clinical efficacy study of its flagship avenanthramides product being developed ...

Q4 2024 Earnings Call Transcript March 10, 2025 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change ...

RPESC-RPE-4W is a proprietary retinal pigment epithelium cell therapy for patients with dry age-related macular degeneration.

Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of ...

Q4 2024 Earnings Call Transcript March 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Fourth ...

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).

Enrollment is now complete in the CORAL clinical trial of nalbuphine ER, to be marketed as Haduvio, for IPF patients with ...

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).